Targeting CD22 in B-cell malignancies: current status and clinical outlook

L Sullivan-Chang, RT O'Donnell, JM Tuscano - BioDrugs, 2013 - Springer
CD22 is a B-cell-specific transmembrane glycoprotein found on the surface of most B cells; it
modulates B-cell function, survival and apoptosis. CD22 has emerged as an ideal target for …

Assessment of coronary artery disease with computed tomography angiography and inflammatory and immune activation biomarkers among adults with HIV eligible …

…, MS Huaman, Q Truong, R Fry, RT O'Donnell… - JAMA Network …, 2021 - jamanetwork.com
Importance Cardiovascular disease (CVD) is increased among people with HIV (PWH), but
little is known regarding the prevalence and extent of coronary artery disease (CAD) and …

[PDF][PDF] Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates

…, SJ DeNardo, GL DeNardo, RT O'Donnell… - Journal of Nuclear …, 1998 - Soc Nuclear Med
Radioimmunotherapy (RIT) with^-labeled immunoconjugates has shown promise in clinical
trials. The macrocyclic chelating agent 1, 4, 7, 10-tetraazacyclododecane-N, N', N", N"'-…

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐H odgkin lymphoma

…, M Abedi, J Welborn, RT O'Donnell - British journal of …, 2014 - Wiley Online Library
This phase II study evaluated the safety and efficacy of lenalidomide in combination with
rituximab in patients with relapsed/refractory, indolent non‐ H odgkin lymphoma ( NHL ). …

Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N …

…, GL DeNardo, A Yuan, CM Richman, RT O'Donnell… - Clinical cancer …, 2003 - AACR
Purpose: Radioimmunotherapy delivered by radiometal immunoconjugates and followed by
marrow support is dose limited by deposition of radioactivity in normal organs. To increase …

[PDF][PDF] A Clinical trial of radioimmunotherapy with 67Cu-21T-BAT-Lym-1 for non-Hodgkin's lymphoma

RT O'Donnell, GL DeNardo, DL Kukis… - Journal of Nuclear …, 1999 - Soc Nuclear Med
Resufts: 67Cu-2lT-BAT-Lym-1providedgoodimagingof NHL and favorable radiation dosimetry.
The mean radiation ratios of tumor to body and tumor to marrow were 28: 1 and 15: 1, …

… breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti …

CM Richman, SJ DeNardo, RT O'Donnell, A Yuan… - Clinical cancer …, 2005 - AACR
Purpose: Although radioimmunotherapy alone is effective in lymphoma, its application to
solid tumors will likely require a combined modality approach. In these phase I studies, …

Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma

…, JS Lee, J Luo, JM Tuscano, RT O'Donnell… - Molecular …, 2012 - ACS Publications
Vincristine (VCR) is a potent anticancer drug, but its clinical efficacy is limited by neurotoxicity.
The field of drug delivery may provide an opportunity to increase the therapeutic index of …

[PDF][PDF] Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body

…, GL DeNardo, G Sgouros, RT O'Donnell… - Journal of nuclear …, 1999 - Soc Nuclear Med
@ S (RM@ — h) X m@/mRB, E4@. 2 where h is other organ sources excluding RM, mm is
the mass of the total body (TB) and S (RM@ — TB) is the S value from TB to RM. For …

[PDF][PDF] Radioimmunotherapy for breast cancer using indium-lll/yttrium-90 BrE-3: results of a phase I clinical trial

SJ DeNardo, EL Kramer, RT O'Donnell… - Journal of Nuclear …, 1997 - Soc Nuclear Med
JSreast cancer strikes 182,000 people yearly in the United States, and 46,000 deaths a year
are attributable to this disease (/). Patients with localized disease can be cured by surgery …